The histone H3K9 demethylase KDM3A promotes anoikis by transcriptionally activating pro-apoptotic genes BNIP3 and BNIP3L

  1. Victoria E Pedanou
  2. Stéphane Gobeil
  3. Sébastien Tabariès
  4. Tessa M Simone
  5. Lihua Julie Zhu
  6. Peter M Siegel
  7. Michael R Green  Is a corresponding author
  1. Howard Hughes Medical Institute, University of Massachusetts Medical School, United States
  2. Université Laval, Canada
  3. McGill University, Canada

Abstract

Epithelial cells that lose attachment to the extracellular matrix undergo a specialized form of apoptosis called anoikis. Here, using large-scale RNA interference (RNAi) screening, we find that KDM3A, a histone H3 lysine 9 (H3K9) mono- and di-demethylase, plays a pivotal role in anoikis induction. In attached breast epithelial cells, KDM3A expression is maintained at low levels by integrin signaling. Following detachment, integrin signaling is decreased resulting in increased KDM3A expression. RNAi-mediated knockdown of KDM3A substantially reduces apoptosis following detachment and, conversely, ectopic expression of KDM3A induces cell death in attached cells. We find that KDM3A promotes anoikis through transcriptional activation of BNIP3 and BNIP3L, which encode pro-apoptotic proteins. Using mouse models of breast cancer metastasis we show that knockdown of Kdm3a enhances metastatic potential. Finally, we find defective KDM3A expression in human breast cancer cell lines and tumors. Collectively, our results reveal a novel transcriptional regulatory program that mediates anoikis.

Data availability

The following data sets were generated

Article and author information

Author details

  1. Victoria E Pedanou

    Department of Molecular, Cell and Cancer Biology, Howard Hughes Medical Institute, University of Massachusetts Medical School, Worcester, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Stéphane Gobeil

    Department of Molecular Medicine, Université Laval, Quebec City, Canada
    Competing interests
    The authors declare that no competing interests exist.
  3. Sébastien Tabariès

    Department of Medicine, McGill University, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  4. Tessa M Simone

    Department of Molecular, Cell and Cancer Biology, Howard Hughes Medical Institute, University of Massachusetts Medical School, Worcester, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Lihua Julie Zhu

    Department of Molecular, Cell and Cancer Biology, Howard Hughes Medical Institute, University of Massachusetts Medical School, Worcester, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Peter M Siegel

    Department of Medicine, McGill University, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  7. Michael R Green

    Department of Molecular, Cell and Cancer Biology, Howard Hughes Medical Institute, University of Massachusetts Medical School, Worcester, United States
    For correspondence
    michael.green@umassmed.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3017-3298

Funding

National Institutes of Health (R01GM033977)

  • Michael R Green

Howard Hughes Medical Institute (68101)

  • Michael R Green

U.S. Department of Defense (BC060871)

  • Michael R Green

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Ali Shilatifard, Northwestern University, United States

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols of the University of Massachusetts Medical School (A-2300) and McGill University. All surgery was performed under sodium pentobarbital anesthesia, and every effort was made to minimize suffering.

Human subjects: This study was approved by the institutional review boards at the University of Massachusetts Medical School (UMMS) and the Mayo Clinic. Consent to publish is not necessary as all patient samples were de-identified.

Version history

  1. Received: April 12, 2016
  2. Accepted: July 28, 2016
  3. Accepted Manuscript published: July 29, 2016 (version 1)
  4. Version of Record published: August 19, 2016 (version 2)

Copyright

© 2016, Pedanou et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,772
    views
  • 466
    downloads
  • 19
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Victoria E Pedanou
  2. Stéphane Gobeil
  3. Sébastien Tabariès
  4. Tessa M Simone
  5. Lihua Julie Zhu
  6. Peter M Siegel
  7. Michael R Green
(2016)
The histone H3K9 demethylase KDM3A promotes anoikis by transcriptionally activating pro-apoptotic genes BNIP3 and BNIP3L
eLife 5:e16844.
https://doi.org/10.7554/eLife.16844

Share this article

https://doi.org/10.7554/eLife.16844

Further reading

    1. Cancer Biology
    2. Cell Biology
    Dongyue Jiao, Huiru Sun ... Kun Gao
    Research Article

    Enhanced protein synthesis is a crucial molecular mechanism that allows cancer cells to survive, proliferate, metastasize, and develop resistance to anti-cancer treatments, and often arises as a consequence of increased signaling flux channeled to mRNA-bearing eukaryotic initiation factor 4F (eIF4F). However, the post-translational regulation of eIF4A1, an ATP-dependent RNA helicase and subunit of the eIF4F complex, is still poorly understood. Here, we demonstrate that IBTK, a substrate-binding adaptor of the Cullin 3-RING ubiquitin ligase (CRL3) complex, interacts with eIF4A1. The non-degradative ubiquitination of eIF4A1 catalyzed by the CRL3IBTK complex promotes cap-dependent translational initiation, nascent protein synthesis, oncogene expression, and cervical tumor cell growth both in vivo and in vitro. Moreover, we show that mTORC1 and S6K1, two key regulators of protein synthesis, directly phosphorylate IBTK to augment eIF4A1 ubiquitination and sustained oncogenic translation. This link between the CRL3IBTK complex and the mTORC1/S6K1 signaling pathway, which is frequently dysregulated in cancer, represents a promising target for anti-cancer therapies.

    1. Biochemistry and Chemical Biology
    2. Cell Biology
    Natalia Dolgova, Eva-Maria E Uhlemann ... Oleg Y Dmitriev
    Research Article Updated

    Mediator of ERBB2-driven cell motility 1 (MEMO1) is an evolutionary conserved protein implicated in many biological processes; however, its primary molecular function remains unknown. Importantly, MEMO1 is overexpressed in many types of cancer and was shown to modulate breast cancer metastasis through altered cell motility. To better understand the function of MEMO1 in cancer cells, we analyzed genetic interactions of MEMO1 using gene essentiality data from 1028 cancer cell lines and found multiple iron-related genes exhibiting genetic relationships with MEMO1. We experimentally confirmed several interactions between MEMO1 and iron-related proteins in living cells, most notably, transferrin receptor 2 (TFR2), mitoferrin-2 (SLC25A28), and the global iron response regulator IRP1 (ACO1). These interactions indicate that cells with high-MEMO1 expression levels are hypersensitive to the disruptions in iron distribution. Our data also indicate that MEMO1 is involved in ferroptosis and is linked to iron supply to mitochondria. We have found that purified MEMO1 binds iron with high affinity under redox conditions mimicking intracellular environment and solved MEMO1 structures in complex with iron and copper. Our work reveals that the iron coordination mode in MEMO1 is very similar to that of iron-containing extradiol dioxygenases, which also display a similar structural fold. We conclude that MEMO1 is an iron-binding protein that modulates iron homeostasis in cancer cells.